What Are the Challenges in Targeting PLC in Cancer Therapy?
One of the major challenges in targeting PLC is the potential for off-target effects, as PLC enzymes are involved in numerous physiological processes. Another challenge is the redundancy and compensation among different PLC isoforms, which may reduce the efficacy of isoform-specific inhibitors. Additionally, cancer cells often develop resistance to targeted therapies, necessitating combination approaches to overcome this hurdle.
